Fragment, Modified GRF, Ipamorelin 12mg (Blend)

HGH Fragment 176-191 6mg, Modified GRF 3mg, Ipamorelin 3mg (12mg Total Blend)

75.00 USD

Availability: In stock

  • Buy 3 for $72.50 each and save 4%
  • Buy 5 for $70.00 each and save 7%
  • Buy 10 for $68.50 each and save 9%

FREE Shipping for orders over $200 (USA Only)

$15.00 Flat Rate Shipping Worldwide (Most Countries) 

*Includes one 30mL Bacteriostatic Water with orders over $300.00

Fragment, Modified GRF, Ipamorelin 12mg (Blend)

Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

Research has shown that achieving maximum natural growth hormone (GH) release by the anterior pituitary can be accomplished, in general, by combining a growth hormone releasing hormone (GHRH) analogue with a growth hormone secretagogue receptor (GHSR) agonist. There are multiple combinations that can accomplish this goal, including combining modified GRF with ipamorelin. Of course, sometimes the goal might be to achieve more specific effects in addition to maximum GH release. In other words, by fine tuning the types of GHRH agonist and GHSR agonist used, it could be possible to create more targeted outcomes.

In the case of Modified GRF, a potent GHRH analogue, the effects go beyond simply boosting GH release. The peptide has been shown, in animal studies, to have benefits in intestinal inflammation, heart function, and wound healing[1], [2], [3].

By adding ipamorelin to the mix with modified GRF, GH release is pulsed to its maximum level. Ipamorelin, known for its specificity in boosting GH with few additional effects, has recently been linked to bone regrowth and matrix stabilization. These effects appear to be in addition to the bone benefits of enhanced GH release[4], [5].

Finally, it is possible to boost targeted fat burning, something that both modified GRF and ipamorelin cause to a limited degree, with the aid of fragment 176-191. While technically a GHRH agonist, fragment 176-191 has been shown in animal models to be a primary and potent stimulator of adipocyte catabolism (fat burning). The peptide is orders of magnitude more potent than most GHRH agonists in stimulating fat metabolism and thus is sometimes referred to as the “lipolytic fragment.” Adding fragment 176-191 to the mix is a way to boost fat burning, particularly in the setting of enhanced GH release, and shift metabolism toward the accumulation of lean body mass[6]–[8].

About The Author

Research by L. Edmiston, M.D. for Peptide Sciences. L. Edmiston holds an M.D. from Case Western Reserve University School of Medicine and a B.S. in molecular biology.


  • [1] T. Ito et al., “GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity,” Peptides, vol. 22, no. 7, pp. 1139–1151, Jul. 2001. [PubMed]
  • [2] M. Waelbroeck, P. Robberecht, D. H. Coy, J.-C. Camus, P. D. Neef, and J. Christophe, “Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRF Analogs with Vasoactive Intestinal Peptide (VIP) Receptors of Rat Pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(l-29)-NH2 as a VIP Antagonist,” Endocrinology, vol. 116, no. 6, pp. 2643–2649, Jun. 1985. [PubMed]
  • [3] A. V. Schally, X. Zhang, R. Cai, J. M. Hare, R. Granata, and M. Bartoli, “Actions and potential therapeutic applications of growth hormone-releasing hormone agonists,” Endocrinology. [PubMed]
  • [4] N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]
  • [5] J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]
  • [6] M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. [PubMed]
  • [7] R. Ferrer-Lorente, C. Cabot, J.-A. Fernández-López, and M. Alemany, “Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats,” Life Sci., vol. 77, no. 16, pp. 2051–2058, Sep. 2005. [PubMed]
  • [8] F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. [PubMed]